Sign Out
Pregnancy: The safety of desvenlafaxine in human pregnancy has not been established. It is demonstrated that desvenlafaxine crosses the human placenta. Desvenlafaxine must only be administered to pregnant women if the expected benefits outweigh the possible risks. If desvenlafaxine is used until, or shortly before birth, discontinuation effects in the newborn should be considered. It is demonstrated that desvenlafaxine crosses the placenta.
Exposure to SNRIs in mid to late pregnancy may increase the risk for preeclampsia, and exposure to SNRIs near delivery may increase the risk for postpartum hemorrhage.
Lactation: Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. No adverse events occurred in either the lactating mothers or the nursing infants, however, the effect in infants have not been established. Desvenlafaxine should only be taken by lactating women if the expected benefits outweigh the possible risks.
